CDX
MKN-45
Tumor indication
Esophageal, Gastric
Tumor subtype
Gastric Adenocarcinoma
Description
MKN-45 (Gastric Cancer CDX Model)
The MKN-45 gastric cancer line was derived from a poorly differentiated stomach adenocarcinoma. It is c-MET–amplified, making it clinically relevant for targeted therapy research. MKN-45 is widely applied in drug screening and biomarker studies for gastric cancer. Its defined mutation profile provides translational value in oncology research.
Key Features:
- Derived from poorly differentiated gastric adenocarcinoma.
- c-MET amplification.
- Aggressive tumor growth in xenografts.
- Reliable gastric cancer research model.
Applications:
MKN-45 supports research into c-MET–targeted therapies. It is also used to explore drug resistance and biomarker validation in gastric cancer. Researchers employ it in translational studies of stomach cancer progression. Its reproducibility makes it valuable for drug development pipelines.
Details
- Tumor indication
- Esophageal, Gastric
- Tumor subtype
- Gastric Adenocarcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.